Assenagon Asset Management S.A. Reduces Holdings in AngioDynamics, Inc. (NASDAQ:ANGO)

Assenagon Asset Management S.A. reduced its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 35.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 272,307 shares of the medical instruments supplier’s stock after selling 152,801 shares during the quarter. Assenagon Asset Management S.A. owned about 0.67% of AngioDynamics worth $2,494,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ANGO. Segall Bryant & Hamill LLC increased its position in shares of AngioDynamics by 142.7% during the third quarter. Segall Bryant & Hamill LLC now owns 911,443 shares of the medical instruments supplier’s stock worth $7,091,000 after purchasing an additional 535,958 shares in the last quarter. Millennium Management LLC increased its position in AngioDynamics by 41.9% during the second quarter. Millennium Management LLC now owns 1,793,454 shares of the medical instruments supplier’s stock worth $10,850,000 after buying an additional 529,861 shares during the period. Systematic Financial Management LP increased its position in AngioDynamics by 14.3% during the third quarter. Systematic Financial Management LP now owns 2,410,346 shares of the medical instruments supplier’s stock worth $18,752,000 after buying an additional 300,785 shares during the period. JPMorgan Chase & Co. lifted its stake in AngioDynamics by 28.7% in the third quarter. JPMorgan Chase & Co. now owns 553,161 shares of the medical instruments supplier’s stock valued at $4,304,000 after buying an additional 123,271 shares during the last quarter. Finally, Royce & Associates LP boosted its holdings in shares of AngioDynamics by 10.8% in the third quarter. Royce & Associates LP now owns 986,073 shares of the medical instruments supplier’s stock valued at $7,672,000 after acquiring an additional 96,138 shares during the period. 89.43% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on ANGO shares. Canaccord Genuity Group cut their target price on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, October 4th. HC Wainwright upped their target price on shares of AngioDynamics from $14.00 to $15.00 and gave the company a “buy” rating in a report on Friday, January 10th.

Insider Buying and Selling

In related news, SVP Warren Nighan, Jr. sold 4,060 shares of the company’s stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $12.31, for a total transaction of $49,978.60. Following the transaction, the senior vice president now owns 41,817 shares of the company’s stock, valued at $514,767.27. This represents a 8.85 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 5.40% of the stock is currently owned by corporate insiders.

AngioDynamics Trading Up 1.0 %

NASDAQ:ANGO opened at $12.06 on Thursday. The stock’s 50 day simple moving average is $8.95 and its 200-day simple moving average is $7.77. AngioDynamics, Inc. has a 12-month low of $5.26 and a 12-month high of $13.13. The firm has a market cap of $488.07 million, a P/E ratio of -2.14 and a beta of 0.59.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.07. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The company had revenue of $72.90 million for the quarter, compared to analysts’ expectations of $70.93 million. During the same period in the previous year, the company posted ($0.05) EPS. AngioDynamics’s revenue was down .1% compared to the same quarter last year. Research analysts forecast that AngioDynamics, Inc. will post -0.37 EPS for the current fiscal year.

AngioDynamics Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.